Last reviewed · How we verify

NCT06211127

Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions

Status unknown NA Last updated 18 January 2024
What this trial tests

NA trial testing Cold laser plaque ablation in Arterial Disease of Legs in 110 participants. Status unknown.

Timeline
16 October 2023
Primary endpoint
30 June 2024
31 December 2024

Quick facts

Lead sponsorXuanwu Hospital, Beijing
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment110
Start date16 October 2023
Primary completion30 June 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 85, any sex, with Arterial Disease of Legs or Atherosclerosis of Artery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, randomized controlled study, which evaluates the effectiveness and safety of cold laser plaque ablation for lower limb arterial stenosis and occlusive lesions from intermittent claudication to chronic threatening limb ischemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. First in man: a novel 355 nm laser plaque ablation system for peripheral artery disease.
    Wang H, Guo L, Zhang Y, Zhu R, et al · · 2025 · PMID 40397243 · DOI 10.1007/s10103-025-04490-z

Verify or expand the search:

Other recruiting trials for Arterial Disease of Legs

Currently open trials in the same condition.

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing